Reported Sunday, Alnylam Presents Results From The KARDIA-2 Phase 2 Study Of Zilebesiran Added To Standard Of Care Antihypertensives In Patients With Inadequately Controlled Hypertension
Reported Sunday, Alnylam Presents Results From The KARDIA-2 Phase 2 Study Of Zilebesiran Added To Standard Of Care Antihypertensives In Patients With Inadequately Controlled Hypertension
據週日報道，Alnylam公佈了針對Zilebesiran的 KARDIA-2 2期研究結果，該研究已添加到治療標準中的高血壓控制不當患者的抗高血壓藥中
- Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent Study Cohorts at Month 3
- A Single Dose of Zilebesiran Resulted in Clinically Significant Additive Reductions in Office Systolic Blood Pressure at Month 3 and in Time-Adjusted Office Systolic Blood Pressure at Month 6 Across Three Independent Study Cohorts
- Zilebesiran Demonstrated an Encouraging Safety and Tolerability Profile When Added to Standard of Care Antihypertensives
- 該研究達到了主要終點，表明三個獨立研究隊列的動態收縮壓在第3個月有臨床顯著降低，最高可達12.1 mmHg
- 在三個獨立研究群組中，單劑量的Zilebesiran使辦公室收縮壓在第3個月顯著降低，在第6個月使經時間調整的辦公室收縮壓明顯降低
- 將Zilebesiran添加到護理標準抗高血壓藥中後表現出令人鼓舞的安全性和耐受性